Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

被引：2
|
作者：
Bernstein, Ezra [1 ]
Luo, Jia [2 ]
Wang, Kaiwen [3 ]
Negrao, Marcelo V. [4 ]
Janne, Pasi A. [2 ]
Sabari, Joshua K. [5 ]
机构：
[1] NYU, Langone Dept Internal Med, 251 East 33rd St, New York, NY 10016 USA
[2] Dana Faber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX USA
[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
D O I：
10.1200/PO.23.00447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Case series demonstrates activity of adagrasib in untreated CNS metastases across multiple scenarios.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases
    Negrao, Marcelo V.
    Spira, Alexander I.
    Heist, Rebecca S.
    Jaenne, Pasi A.
    Pacheco, Jose M.
    Weiss, Jared
    Gadgeel, Shirish M.
    Velastegui, Karen
    Yang, Wenjing
    Der-Torossian, Hirak
    Christensen, James G.
    Sabari, Joshua K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4472 - +
  • [2] The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer
    Murciano-Goroff, Yonina R.
    Lito, Piro
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (11) : 677 - 678
  • [3] The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
    Yonina R. Murciano-Goroff
    Piro Lito
    Nature Reviews Clinical Oncology, 2022, 19 : 677 - 678
  • [4] Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
    Sabari, Joshua K.
    Spira, Alexander I.
    Heist, Rebecca Suk
    Janne, Pasi A.
    Pacheco, Jose M.
    Weiss, Jared
    Gadgeel, Shirish M.
    Der-Torossian, Hirak
    Velastegui, Karen
    Kheoh, Thian
    Christensen, James G.
    Negrao, Marcelo Vailati
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [5] Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Rosner, Samuel
    FUTURE ONCOLOGY, 2023, 19 (15) : 1037 - 1051
  • [6] Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
    Luo, Jia
    Villaruz, Liza C.
    LANCET RESPIRATORY MEDICINE, 2024, 12 (08): : 576 - 577
  • [7] KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
    Spira, Alexander I.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca Suk
    Ou, Sai-Hong Ignatius
    Pacheco, Jose Maria
    Johnson, Melissa Lynne
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo Vailati
    Pennell, Nathan A.
    Zhang, Jun
    Velastegui, Karen
    Christensen, James G.
    Yan, Xiaohong
    Anderes, Kenna Lynn
    Chao, Richard C.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review
    Luo, Jia
    Florez, Narjust
    Donnelly, Anjali
    Lou, Yanyan
    Lu, Kevin
    Ma, Patrick C.
    Spira, Alexander I.
    Ryan, Debra
    Husain, Hatim
    JCO PRECISION ONCOLOGY, 2024, 8
  • [9] Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
    Zhang, Jun
    Johnson, Melissa
    Barve, Minal
    Bazhenova, Lyudmila
    McCarthy, Marybeth
    Schwartz, Rowena
    Horvath-Walsh, Elise
    Velastegui, Karen
    Qian, Chunlin
    Spira, Alexander
    ONCOLOGIST, 2023, : 287 - 296
  • [10] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
12345